论文部分内容阅读
目的:探讨新辅助化疗方案在晚期上皮性卵巢癌患者中的治疗效果。方法:系统性回顾42例晚期上皮性卵巢癌患者的临床资料,其中20例患者采用新辅助化疗(NAC),22例患者接受手术治疗,比较二者的手术满意率。结果:NAC组于手术中见病灶部位有坏死,肿瘤易剥离,相对容易切除。术后标本病理学镜检显示肿瘤细胞有不同程度的退行性改变,部分病例切除病灶组织学完全消退。实施肿瘤细胞减灭术后,NAC组(75.00%)远高于PCS组(45.45%),经统计学分析具有差异性(P<0.05)。结论:卵巢癌晚期患者临床上判断行手术治疗比较困难,采用新辅助化疗后可使手术成功率提高,并可有效降低患者术中并发症的发生概率。
Objective: To investigate the therapeutic effect of neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer. Methods: The clinical data of 42 patients with advanced epithelial ovarian cancer were retrospectively reviewed. Among them, 20 patients received neoadjuvant chemotherapy (NAC) and 22 patients received surgical treatment. The surgical satisfaction rate was compared between the two groups. Results: The NAC group showed necrosis in the lesion site during the operation. The tumor was easy to peel off and was relatively easy to resect. Pathological examination showed that the tumor cells had different degrees of degenerative changes in postoperative specimens, and histological resection of some cases completely disappeared. After the cytoreductive surgery, the NAC group (75.00%) was much higher than the PCS group (45.45%), which was statistically significant (P <0.05). Conclusion: It is difficult to determine the surgical treatment of advanced ovarian cancer patients. The neoadjuvant chemotherapy can improve the success rate of operation and reduce the probability of intraoperative complications.